Medicine and Health Sciences Commons^™

Lorealaus: Lorlatinib Real-World Australian Experience In Advanced Alk-Rearranged Nsclc, Marliese Alexander, Joe Wei, Sagun Parakh, Thomas John, Steven Kao, Adnan Nagrial, Samantha Bowyer, Lydia Warburton, Melissa Moore, Brett G. M. Hughes, Timothy D. Clay, Nick Pavlakis, Benjamin J. Solomon, Malinda Itchins

Research outputs 2022 to 2026

Introduction: Over the past decade, ALK tyrosine kinase inhibitors have delivered unprecedented survival for individuals with ALK-positive (ALK+) lung cancers. Real-world data enhance the understanding of optimal drug sequencing and expectations for survival. Methods: Multicenter real-world study of individuals with pretreated advanced ALK+ lung cancers managed on a lorlatinib access program between 2016 and 2020. Key outcomes were lorlatinib efficacy, tolerability, and treatment sequencing. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method among all individuals (PFSa and OSa), with at least 30 days (one-cycle) lorlatinib exposure (PFSb and OSb), and with good performance status (PFSc …